双歧杆菌乳杆菌三联活菌片辅助治疗溃疡性结肠炎患者的效果

Effects of triple viable bifidobacterium lactobacillus tablets in adjuvant treatment of ulcerative colitis

目的:探讨双歧杆菌乳杆菌三联活菌片联合美沙拉嗪、肠炎宁胶囊治疗溃疡性结肠炎(UC)患者的效果。方法:回顾性分析2018年1月至2020年1月该院收治的100例UC患者的临床资料,根据治疗方法不同将其分为对照组和观察组各50例。对照组采用美沙拉嗪联合肠炎宁胶囊治疗,观察组在对照组基础上采用双歧杆菌乳杆菌三联活菌片治疗,比较两组临床疗效,治疗前后肠道菌群数量、血清炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平、肠黏膜屏障功能指标[二胺氧化酶(DAO)、D-乳酸]水平及不良反应发生率。结果:观察组治疗总有效率为92.00%(46/50),高于对照组的76.00%(38/50),差异有统计学意义(P<0.05);治疗2周后,观察组肠道大肠埃希菌数量少于对照组,双歧杆菌数量多于对照组,血清TNF-α、IL-6、hs-CRP、DAO、D-乳酸水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌乳杆菌三联活菌片联合美沙拉嗪、肠炎宁胶囊治疗UC患者效果显著,可调节肠道菌群平衡,降低血清TNF-α、IL-6、hs-CRP水平,修复肠黏膜屏障功能,效果优于单用美沙拉嗪、肠炎宁胶囊治疗。

Objective:To investigate effects of triple viable bifidobacterium lactobacillus tablets combined with Mesalazine and Changyanning capsules in treatment of ulcerative colitis(UC).Methods:The clinical data of 100 UC patients admitted to the hospital from January 2018 to January 2020 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,50 cases in each.The control group was treated with Mesalazine combined with Changyanning capsules,while the observation group was treated with triple viable bifidobacterium lactobacillus tablets additionally.The clinical efficacy,the number of intestinal flora before and after the treatment,the levels of serum inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP)],the intestinal mucosal barrier function index levels[diamine oxidase(DAO),D-lactic acid],and the adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 92.00%(46/50),which was higher than 76.00%(38/50)in the control group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,the number of intestinal Escherichia coli in the observation group was less than that in the control group,the number of Bifidobacterium was more than that in the control group,the levels of serum TNF-α,IL-6,hs-CRP,DAO and D-lactic acid were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Triple viable bifidobacterium lactobacillus tablets combined with Mesalazine and Changyanning capsules have a significant effect in the treatment of the UC patients,which can regulate the balance of intestinal flora,reduce the levels of serum TNF-α,IL-6 and hs-CRP,and repair the intestinal mucosal barrier function.Moreover,it is superior to single Mesalazine and Changyanning capsules treatment.